Regulation of granulopoiesis by transcription factors and cytokine signals

Leukemia

Volumn 14, Issue 6, 2000, Pages 973-990

  Ward, A C ^b   Loeb, D M ^a   Soede Bobok, A A ^c   Touw, I P ^c   Friedman, A D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c NONE

Author keywords

C EBP ; Cytokine receptor; G CSF R; Granulopoiesis; PU.1; Transcription factors

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CYTOKINE RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; HOMEODOMAIN PROTEIN; LEUKOCYTE ELASTASE; LYSOZYME; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE; RETINOBLASTOMA PROTEIN; RETINOIC ACID RECEPTOR; STAT PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTION FACTOR SP1;

BONE MARROW CELL; CELL LINEAGE; CELL MATURATION; GENE EXPRESSION; GENETIC REGULATION; GRANULOCYTE; GRANULOCYTE PRECURSOR; GRANULOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; PROMYELOCYTE; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0034130509     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401808     Document Type: Review

References (327)

1. Ness SA, Kowenz-Leutz E, Casini T, Graf T, Leutz A. Myb and NF-M: combinatorial activators of myeloid genes in heterologous cell types. Genes Dev 1993; 7: 749-759.
2. Suzow J, Friedman AD. The murine myeloperoxidase promoter contains several functional elements - one element binds a cell type-restricted transcription factor, myeloid nuclear factor 1 (MyNF1). Mol Cell Biol 1993; 13: 2141-2151.
3. Nuchprayoon I, Meyers S, Scott LM, Suzow J, Hiebert S, Friedman AD. PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2b/CBFb oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol 1994; 14: 5558-5568.
4. Zhang D-E, Hetherington CJ, Chen H-M, Tenen DG. The macrophage transcription factor PU.1 directs tissue-specific expression of the M-CSF receptor. Mol Cell Biol 1994; 14: 373-381.
5. Zhang D-E, Fujioka K-I, Hetherington CJ, Shapiro LH, Chen H-M, Look AT, Tenen DG. Identification of a region which directs monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol 1994; 14: 8005-8095.
6. Ahne B, Stratling WH. Characterization of a myeloid-specific enhancer of the chicken lysozyme gene. J Biol Chem 1994; 269: 17794-17801.
7. Hohaus S, Petrovick MS, Voso MT, Sun Z, Zhang D-E, Tenen DG. PU.1 (Spi-1 ) and C/EBPa regulate expression of the granulocyte-macrophage colony-stimulating factor receptor a gene. Mol Cell Biol 1995; 15: 5830-5845.
8. Shapiro LH. Myb and Ets proteins cooperate to transactivate an early myeloid gene. J Biol Chem 1995; 270: 8763-8771.
9. Oelgeschläger M, Nuchprayoon I, Lüscher B, Friedman AD. C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter. Mol Cell Biol 1996; 16: 4717-4725.
10. Zhang D-E, Hetherington CJ, Meyers S, Rhoades KL, Larson CJ, Chen H-M, Hiebert SW, Tenen DG. CCAAT/enhancer binding protein (C/EBP) and AML1 (CBFa2) synergistically activate the macrophage-colony stimulating factor receptor promoter. Mol Cell Biol 1996; 16: 1231-1240.
11. Ford AM, Bennett CA, Healy LE, Towatari M, Greaves MF, Enver T. Regulation of the myeloperoxidase enhancer binding proteins PU.1, C/EBPα, β, and δ during granulocyte-lineage specification. Proc. Natl Acad Sci USA 1996; 93: 10838-10843.
12. Smith LT, Hohaus S, Gonzalez DA, Dziennis SE, Tenen DG. PU.1 (Spi-1 ) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood 1996; 88: 1234-1247.
13. Heydemann A, Juan G, Hennessy K, Parmacek MS, Simon MC. The myeloid-specific c-fes promoter is regulated by Sp1, PU.1, and a novel transcription factor. Mol Cell Biol 1996; 16: 1676-1686.
14. Nuchprayoon I, Simkevich CP, Luo M, Rosmarin AC, Friedman AD. An enhancer located between the neutrophil elastase and proteinase 3 promoters is activated by Sp1 and an ets factor. J Biol Chem 1999; 274: 1085-1091.
15. Yamanaka R, Kim GD, Radomska HS, Lekstrom-Himes J, Smith LT, Antonson P, Tenen DG, Xanthopolous KG. CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing. Proc Natl Acad Sci USA 1997; 94: 6462-6467.
16. Yamanaka R, Barlow C, Lekstrom-Himes J, Castilla LH, Liu PP, Eckhaus M, Decker T, Wynshaw-Boris A, Xanthopolous KG. Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. Proc Natl Acad Sci USA 1997; 94: 13187-13192.
17. Shen W-F, Largman C, Lowney P, Corral JC, Detmer K, Hauser CA, Simonitch TA, Hack FM, Lawrence HJ. Lineage-restricted expression of homeobox-containing genes in human hematopoietic cell lines. Proc Natl Acad Sci USA 1989; 86: 8536-8540.
18. Lowney P, Corral J, Detmer K, LeBeau MM, Deaven L, Lawrence HJ, Largman C. A human Hox 1 homeobox gene exhibits myeloid-specific expression of alternative transcripts in human hematopoietic cells. Nucleic Acids Res 1991; 19: 3443-3449.
19. Savageau G, Lansdorp PM, Eaves CL, Hogge DE, Dragowska WH, Reid DS, Largman C, Lawrence HJ, Humphries RK. Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Proc Natl Acad Sci USA 1994; 91: 12223-12227.
20. Frazier GC, Patmasiriwat P, Zhang X, Saunders GF. Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow. Blood 1995; 86: 4704-4706.
21. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo T, Dohy H, Nakauchi H, Ishidate T, Akiyama T, Kishimoto T. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-3079.
22. Graves B, Johnson PF, McKnight SL. Homologous recognition of a promoter domain common to the MSV LTR and the HSV tk gene. Cell 1986; 44: 565-576.
23. Johnson PF, Landschulz WH, Graves BJ, McKnight SL. Identification of a rat liver nuclear protein that binds to the enhancer core element of three animal viruses. Genes Dev 1987; 1: 133-146.
24. Landschulz WH, Johnson PF, Adashi EY, Graves BJ, McKnight SL. Isolation of a recombinant copy of the gene encoding C/EBP. Genes Dev 1988; 2: 786-800.
25. Landschulz WH, Johnson PF, McKnight SL. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 1988; 240: 1759-1764.
26. Landschulz WH, Johnson PF, McKnight SL. The DNA binding domain of the rat liver protein C/EBP is bipartite. Science 1989; 246: 1681-1688.
27. Friedman AD, Landschulz WH, McKnight SL. CCAAT/enhancer binding protein activates the promoter of the serum albumin gene in cultured hepatoma cells. Genes Dev 1989; 3: 1314-1322.
28. Friedman AD, McKnight SL. Identification of two polypeptide segments of CCAAT/enhancer-binding protein required for transcriptional activation of the serum albumin gene. Genes Dev 1990; 4: 1416-1426.
29. Birkenmeier EH, Gwyenn B, Howard S, Jerry J, Gordon JI, Landschulz WH, McKnight SL. Tissue-specific expression, developmental regulation, and genetic mapping of the gene encoding CCAAT/enhancer binding protein. Genes Dev 1989; 3: 1146-1156.
30. Chandrasekaran C, Gordon JI. Cell lineage-specific and differentiation-dependent patterns of CCAAT/enhancer binding protein alpha expression in the gut epithelium of normal and transgenic mice. Proc Natl Acad Sci USA 1993; 90: 8871-8875.
31. Scott LM, Civin CI, Rorth P, Friedman AD. A novel temporal pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood 1992; 80: 1725-1735.
32. Muller C, Kowenz-Leutz E, Grieser-Ada S, Graf T, Leutz A. NF-M (chicken C/EBPβ) induces eosinophilic differentiation and apoptosis in a hematopoietic progenitor cell line. EMBO J 1995; 14: 6127-6135.
33. Radomska HS, Huettner CS, Zhang P, Tenen DG. CCAAT/enhancer binding protein a is a regulatory switch sufficient for induction of granulocytic differentiation from bipotential myeloid cells. Mol Cell Biol 1998; 18: 4301-4314.
34. Nerlov C, McNagny KM, Doderlein G, Kowenz-Leutz E, Graf T. Distinct C/EBP functions are required for eosinophil lineage commitment and maturation. Genes Dev 1998; 12: 2413-2422.
35. Wang X, Scott E, Sawyers CL, Friedman AD. C/EBPα by-passes G-CSF signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood 1999; 94: 560-571.
36. Zhang D-E, Zhang P, Wang N-D, Hetherington CJ, Darlington GJ, Tenen DG. Absence of G-CSF signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice. Proc Natl Acad Sci USA 1997; 94: 569-574.
37. Weiss MJ, Keller G, Orkin SH. Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells. Genes Dev 1994; 8: 1184-1197.
38. Kulessa H, Frampton J, Graf T. GATA-1 reprograms avian myelomonocytic cell lines into eosinophils, thromboblasts, and erythroblasts. Genes Dev 1995; 9: 1250-1262.
39. Screpanti I, Romani L, Musiani P, Modesti A, Fattori E, Lazzaro D, Sellitto C, Scarpa S, Bellavia D, Lattanzio G, Bistoni F, Frati L, Cortese R, Gulino A, Ciliberto G, Coslantini F, Poli V. Lymphoproliferative disorder and imbalanced T-helper response in C/EBPb-deficient mice. EMBO J 1995; 14: 1932-1941.
40. Tanaka T, Akira S, Yoshida M, Umemoto Y, Yoneda N, Shirafuji H, Suematsu S, Yoshida N, Kishimoto T. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell 1995; 80: 353-361.
41. Chen X, Liu W, Ambrosino C, Ruocco MR, Poli V, Romani L, Quinto I, Barbieri S, Holmes KL, Venuta S, Scala G. Impaired generation of bone marrow B lymphocytes in mice deficient in C/EBPα. Blood 1997; 90: 156-164.
42. Lee Y-H, Williams SC, Baer M, Sterneck E, Gonzalez FJ, Johnson PF. The ability of C/EBPβ but not C/EBPα to synergize with an Sp1 protein is specified by the leucine zipper and activation domain. Mol Cell Biol 1997; 17: 2038-2047.
43. Roman C, Platero JS, Shuman JD, Calame K. Ig/EBP-1: a ubiquitously expressed immunoglobulin enhancer binding protein that is similar to C/EBP and heterdimerizes with C/EBP. Genes Dev 1990; 4: 1404-1415.
44. Cooper C, Henderson A, Artandi S, Avitahl N, Calame K. Ig/EBP (C/EBP gamrna) is a transdominant negative inhibitor of C/EBP family transcriptional activators. Nucleic Acids Res 1995; 23: 4371-4377.
45. Antonson P, Stellan B, Yamanaka R, Xanthopoulos KG. A novel human CCAAT/enhancer binding protein gene, C/EBP epsilon, is expressed in cells of lymphoid and myeloid lineages and is localized on chromosome 14q11.2 close to the T cell receptor alpha/delta locus. Genomics 1996; 35: 30-38.
46. Chumakov AM, Grillier I, Chumakov E, Chih D, Slater J, Koeffler HP. Cloning of the novel human myeloid-cell-specific C/EBP-epsilon transcription factor. Mol Cell Biol 1997; 17: 1375-1386.
47. Leckstrom-Himes JA, Dorman SE, Kopar P, Holland SM, Gallin JI. Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein ε. J Exp Med 1999; 189: 1847-1852.
48. Habener JF, Ron D. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factor C/EBP and LAP functions as a dominant-negative inhibitor of gene transcription. Genes Dev 1992; 6: 439-453.
49. Friedman AD. GADD153/CHOP, a DNA damage-inducible protein, reduced CCAAT/enhancer binding protein activities and increased apoptosis in 32D cl3 myeloid cells. Cancer Res 1996; 56: 3250-3256.
50. Klemsz MJ, McKercher SR, Celada A, Van Beveran C, Maki RA. The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell 1990; 61: 113-124.
51. Ray-Gallet D, Mao C, Tavitian A, Moreau-Gachelin F. DNA binding specificities of Spi-1/PU.1 and Spi-B transcription factors and identification of a Spi-1/Spi-B binding site in the c-fes/c-fps promoter. Oncogene 1995; 11: 303-313.
52. Pongubala JMR, Van Beveren C, Nagulapalli S, Klemsz MJ, NcKercher SR, Maki RA, Atchison ML. Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation. Science 1993; 259: 1622-1625.
53. Mao C, Ray-Gallet D, Tavitian A, Moreau-Gachelin F. Differential phosphorylation of Spi-B and Spi-1 transcription factors. Oncogene 1996; 12: 863-873.
54. Celada A, Borras FE, Soler C, Lloberas J, Klemsz M, van Beveren C, McKercher S, Maki RA. The transcription factor PU.1 is involved in macrophage proliferation. J Exp Med 1996; 184: 61-69.
55. Eisenbeis CF, Singh H, Storb U. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev 1995; 9: 1377-1387.
56. Lodie TA, Savedra R Jr, Golenbock DT, Van Beveren CP, Maki RA, Fenton MJ. Stimulation of macrophages by lipopolysaccharide alters the phosphorylation state, conformation, and function of PU.1 via activation of casein kinase II. J Immunol 1997; 158: 1848-1856.
57. Klemsz MJ, Maki RA. Activation of transcription by PU.1 requires both acidic and glutamine domains. Mol Cell Biol 1996; 16: 390-397.
58. Fisher RC, Olson MC, Pongubala JM, Perkel JM, Atchison ML, Scott EW, Simon MC. Normal myeloid development requires both the glutamine-rich domain and the PEST region of transactivation factor PU.1 but not the potent acidic transactivation domain. Mol Cell Biol 1998; 18: 4347-4357.
59. Chen HM, Zhang P, Voso MT, Hohaus S, Gonzalez DA, Glass CK, Zhang DE, Tenen DG. Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. Blood 1995; 85: 2918-2928.
60. Voso MT, Burn TC, Wulf G, Lim B, Leone G, Tenen DG. Inhibition of hematopoiesis by competitive binding of transcription factor PU.1. Proc Natl Acad Sci USA 1994; 91: 7932-7936.
61. Cheng T, Shen H, Giokas D, Gere J, Tenen DG, Scadden DT. Temporal mapping of gene expression levels during the differentiation of individual primary hematopoietic cells. Proc Natl Acad Sci USA 1996; 93: 13158-13163.
62. Nerlov C, Graf T. PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev 1998; 12: 2403-2412.
63. Bellon T, Perrotti D, Calabretta B. Granulocytic differentiation of normal hematopoietic precursor cells induced by transcription factor PU.1 correlates with negative regulation of the c-myb promoter. Blood 1997; 90: 1828-1839.
64. Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994; 265: 1573-1577.
65. McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H, Klemsz M, Feeney AJ, Wu GE, Paige CJ, Maki RA. Targeted disruption of the PU. 1 gene results in multiple hematopoietic abnormalities. EMBO J 1996; 15: 5647-5658.
66. Anderson KL, Smith KA, Pio F, Torbett BE, Maki RA. Neutrophils deficient in PU.1 do not terminally differentiate or become functionally competent. Blood 1998; 92: 1576-1585.
67. DeKoter RP, Walsh JC, Singh H. PU.1 regulates both cytokine-dependent proliferation and differentiation of granulocyte/ macrophage progenitors. EMBO J 1998; 17: 4456-4468.
68. Anderson KL, Smith KA, Conners K, McKercher SR, Maki RA, Torbett BE. Myeloid development is selectively disrupted in PU.1 null mice. Blood 1998; 91: 3702-3710.
69. Anderson KL, Smith KA, Perkin H, Hermanson G, Anderson C-G, Jolly DJ, Maki RA, Torbett BE. PU.1 and the granulocyte- and macrophage colony-stimulating factor receptors play distinct roles in late-stage myeloid cell differentiation. Blood 1999; 94: 2310-2318.
70. Henkel GW, McKercher SR, Leenan PJM, Maki RA. Commitment to the monocytic lineage occurs in the absence of the transcription factor PU.1. Blood 1999; 93: 2849-2858.
71. Lichanska AM, Browne CM, Henkel GW, Murphy KM, Ostrowski MC, McKercher SR, Maki RA, Hume DA. Differentiation of the mononuclear phagocyte system during embryogenesis: the role of transcription factor PU.1. Blood 1999; 94: 127-138.
72. Kamachi Y, Ogawa E, Asano M, Ishida S, Murakami Y, Satake M, Ito Y, Shigesda K. Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer. Mol Cell Biol 1990; 64: 4808-4819.
73. Wang S, Speck NA. Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers. Mol Cell Biol 1992; 12: 89-102.
74. Bae S-C, Yamaguchi-Iwai Y, Ogawa E, Maruyama M, Inuzuka M, Kagoshima H, Shigesada K, Satake M, Ito Y. Isolation of PEBP2αB cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1. Oncogene 1993; 8: 809-814.
75. Wang S, Wang Q, Crute BE, Melnikova IN, Keller SR, Speck NA. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol 1993; 13: 3324-3339.
76. Ogawa E, Maruyama M, Kagoshima H, Inuzuka M, Lu J, Satake M, Shigesada K, Ito Y. PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosphila runt gene and the human AML1 gene. Proc Natl Acad Sci USA 1993; 90: 6859-6863.
77. Ogawa E, Inuzuka M, Maruyamna M, Satake M, Naito-Fujimoto M, Ito Y, Shigesada K. Molecular cloning and characterization of PEBP2β, the heterodimeric partner of a novel Drosophila runtrelated DNA binding protein PEBP2α. Virology 1993; 194: 314-331.
78. Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L, Groner Y. AML1, 2 and 3. The human members of the runt domain gene-family. Genomics 1994; 23: 425-432.
79. Kania MA, Bonner AS, Duffy JB, Gergen JP. The Drosophila segmentation gene runt encodes a novel nuclear regulatory protein that is also expressed in the developing nervous system. Genes Dev 1990; 4: 1701-1713.
80. Meyers S, Downing JR, Hiebert SW. Identification of AML1 and the (8:21) translocation protein AML1-ETO as sequence specific DNA binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 1993; 13: 6336-6345.
81. Melnikova IN, Crute BE, Wang S, Speck NA. Sequence specificity of the core-binding factor. J Virol 1993; 67: 2408-2411.
82. Lenny N, Meyers S, Hiebert SW. Functional domains of the t(8;21) fusion protein, AML1-ETO. Oncogene 1995; 11: 1761-1769.
83. Crute BE, Lewis AF, Wu Z, Bushweller JH, Speck NA. Biochemical and biophysical properties of the core-binding factor α2 (AML1) DNA-binding domain. J Biol Chem 1996; 271: 26251-26260.
84. Kanno T, Kanno Y, Chen L-F, Ogawa E, Kim W-Y, Ito Y. Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor a subunit revealed in the presence of the β subunit. Mol Cell Biol 1998; 18: 2444-2454.
85. Wotton D, Ghysdael J, Wang S, Speck NA, Owen MJ. Cooperative binding of ets-1 and core binding factor to DNA. Mol Cell Biol 1994; 14: 840-850.
86. Hernandez-Munain C, Krangel MS. Regulation of the T-cell receptor δ enhancer by functional cooperation between c-Myb and core binding factors. Mol Cell Biol 1994; 14: 473-483.
87. Sun W, Graves BJ, Speck NA. Transactivation of the moloney murine leukemia virus and T-cell receptor β-chain enhancers by cbf and ets requires intact binding sites for both proteins. J Virol 1995; 69: 4941-4949.
88. Giese K, Kingsley C, Kirshner JR, Grosschedl R. Assembly and function of a TCR alpha enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions. Genes Dev 1995; 9: 995-1008.
89. Britos-Bray M, Friedman AD. Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-myb. Mol Cell Biol 1997; 17: 5127-5135.
90. Petrovick MS, Hiebert SW, Friedman AD, Hetherington CJ, Tenen DG, Zhang D-E. Multiple functional domains of AML1: PU.1 and C/EBPα synergize with different regions of AML1. Mol Cell Biol 1998; 18: 3915-3925.
91. Yagi R, Chen L-F, Shigesada K, Murakami Y, Ito Y. A WW domain-containing Yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 1999; 18: 2551-2562.
92. Kim W-Y, Sieweke M, Ogawa E, Wee H-J, Englmeier U, Graf T, Ito Y. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J 1999; 6: 1609-1620.
93. Aronson BD, Fisher AL, Blechman K, Caudy M, Gergen JP. Groucho-dependent and -independent repression activities of runt domain proteins. Mol Cell Biol 1997; 17: 5581-5587.
94. Imai Y, Kurokawa M, Tanaka K, Friedman AD, Ogawa S, Mitani K, Yazaki Y, Hirai H. TLE, the human homolog of groucho, interacts with AML1 and acts as a represser of AML1-induced transactivation. Biochem Biophys Res Commun 1998; 252: 582-589.
95. Levanon D, Goldstein RE, Bernstein Y, Tang H, Goldenberg D, Stifani S, Paroush Z, Groner Y. Transcriptional repression by AML1 and LEF-1 is mediated by TLE/groucho corepressors. Proc Natl Acad Sci USA 1998; 95: 11590-11595.
96. Lutterbach B, Westendorf JJ, Linggi B, Hiebert SW. AML-1, a target of multiple chromosomal translocations in acute leukemia, interacts with mSin3 to repress transcription from the p21/WAF1/CIP1 promoter. Blood 1998; 92: 508a.
97. Fenrick R, Amann JM, Lutterbach B, Wing L, Westendorf JJ, Downing JR, Hiebert SW. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol Cell Biol 1999; 19: 6566-6574.
98. Tanaka T, Kurokawa M, Ueki K, Tanaka K, Imai Y, Mitani K, Okazaki K, Sagata N, Yazaki Y, Shibata Y, Kadowaki T, Hirai H. The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol 1996; 16: 3967-3979.
99. Satake M, Inuzuka M, Shigesada K, Oikawa T, Ito Y. Differential expression of subspecies of polyomavirus and murine leukemia virus enhancer core binding protein, PEBP2, in various hematopoietic cells. Jpn J Cancer Res 1992; 83: 714-722.
100. Erickson P, Dessev G, Lasher RS, Philips G, Robinson M, Drabkin H. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Blood 1996; 88: 1813-1823.
101. Zeng C, van Wijnen AJ, Stein JL, Meyers S, Sun W, Shopland L, Lawrence JB, Penman S, Lian JB, Stein GS, Hiebert SW. Identification of a nuclear matrix targeting signal in the leukemia and bone-related AML/CBF-a transcription factors. Proc Natl Acad Sci USA 1998; 94: 6746-6751.
102. Corsetti MT, Calabi F. Lineage- and stage-specific expression of runt box polypeptides in primitive and definitive hematopoiesis. Blood 1997; 89: 2359-2368.
103. North T, Gu T-L, Stacy T, Wang Q, Howard L, Binder M, Marin-Padilla M, Speck NA. Cbfa2 is required for the formation of intraaortic hematopoietic clusters. Development 1999; 126: 2563-2575.
104. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML-1, the target of multiple chromosomal translocations in human leukemia, is essential for normal murine fetal hematopoiesis. Cell 1996; 84: 321-330.
105. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 1996; 93: 3444-3449.
106. Wang Q, Stacy T, Miller JD, Lewis AF, Gu T-L, Huang X, Bushweller JH, Bories J-C, Alt FW, Ryan G, Liu PP, Wynshaw-Boris A, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. The CBFβ subunit is essential for CBFa2 (AML1 ) function in vivo. Cell 1996; 87: 697-708.
107. Sasaki K, Yagi H, Bronson RT, Tominaga K, Matsunashi T, Deguchi K, Tani Y, Kishimoto T, Komori T. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor β. Proc Natl Acad Sci USA 1996; 93: 12359-12363.
108. Niki M, Okada H, Takano H, Kujo J, Tani K, Hibino H, Asano S, Ito Y, Satake M, Noda T. Hematopoiesis in the fetal liver is impaired by the targeted mutagenesis of the gene encoding a non-DNA binding subunit of the transcription factor, PEBP2/CBF. Proc Natl Acad Sci USA 1997; 94: 5697-5702.
109. Cao W, Britos-Bray M, Claxton DF, Kelley CA, Speck NA, Liu PP, Friedman AD. CBFβ-SMMHC, expressed in M4eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells. Oncogene 1997; 15: 1315-1327.
110. Cao W, Adya N, Britos-Bray M, Liu PP, Friedman AD. The core binding factor a interaction domain and the smooth muscle myosin heavy chain segment of CBFβ-SMMHC are both required to slow cell proliferation. J Biol Chem 1998; 273: 31534-31540.
111. Klempnauer KH, Sippel AE. The highly conserved amino-terminal region of the protein encoded by the v-myb oncogene functions as a DNA-binding domain. EMBO J 1987; 6: 2719-2725.
112. Biedenkapp H, Borgemeyer U, Sippel AE, Kempnauer KH. Viral myb oncogene encodes a sequence-specific DNA-binding activity. Nature 1988; 335: 835-837.
113. Tanikawa J, Yasukawa T, Enari M, Ogata K, Nishimura Y, Ishii S, Sarai A. Recognition of specific DNA sequences by the c-myb protooncogene product: role of three repeat units in the DNA-binding domain. Proc Natl Acad Sci USA 1993; 90: 9320-9324.
114. Ogata K, Morikawa S, Nakamura H, Sekikawa A, Saski M, Nagadoi A, Sarai A, Ishii S, Nishimura Y. Solution structure of a specific DNA complex of the myb DNA-binding domain with cooperative recognition helices. Cell 1994; 79: 639-648.
115. Ogata K, Hojo H, Aimoto S, Nakai T, Nakamura H, Sarai A, Ishii S, Nishimura Y. Solution structure of a DNA-binding unit of myb: a helix-turn-helix-related motif with conserved tryptophans forming a hydrophobic core. Proc Natl Acad Sci USA 1992; 89: 6428-6432.
116. Nomura N, Takahashi M, Matsui M, Ishii S, Date T, Sasamoto S, Ishizaki R. Isolation of human cDNA clones of myb-related genes, A-myb and B-myb. Nucleic Acids Res 1988; 16: 11075-11089.
117. Trauth K, Mutschler B, Jenkins NA, Gilbert DJ, Copeland NG, Klempnauer KH. Mouse A-myb encodes a transactivator and is expressed in mitotically active cells of the developing CNS, adult tests and B-lymphocytes. EMBO J 1994; 13: 5994-6005.
118. Weston K, Bishop MJ. Transcriptional activation by the v-myb oncogene and its cellular progenitor, c-myb. Cell 1989; 58: 85-93.
119. Sakura H, Kanei-Ishii C, Nagase T, Nakagoshi H, Gonda TJ. Delineation of three functional domains of the transcriptional activator encoded by the c-myb proto-oncogene. Proc Natl Acad Sci USA 1989; 86: 5758-5762.
120. Ibanez CE, Lipsick JS. Transactivation of gene expression by v-myb. Mol Cell Biol 1990; 10: 2285-2293.
121. Dash AB, Orrico FC, Ness SA. The EVES motif mediates both intermolecular and intramolecular regulation of c-myb. Genes Dev 1999; 10: 1858-1869.
122. Oelgeschläger M, Krieg J, Luscher-Fierzlaff JM, Luscher B. Casein kinase II phosphorylation site mutations in c-myb affect DNA binding and transcriptional cooperativity with NF-M. Mol Cell Biol 1995; 15: 5966-5974.
123. Aziz N, Miglarese MR, Hendrickson RC, Shabanowitz J, Sturgill TW, Hunt DF, Bender TP. Modulation of c-myb-induced transcription activation by a phosphorylation site near the negative regulatory domain. Proc Natl Acad Sci USA 1995; 92: 6429-6433.
124. Nomura T, Sakai N, Sarai A, Sudo T, Kanei-Ishii C, Ramsay RG, Favier D, Gonda TJ, Ishii S. Negative autoregulation of c-myb activity by homodimer formation through the leucine zipper. J Biol Chem 1993; 268: 21914-21923.
125. Ramsey RG, Morrice N, Van Eeden P, Kanagasundaram V, Nomura T, De Blaquierre J, Ishii S, Wettenhall R. Regulation of c-myb through protein phosphorylation and leucine zipper interactions. Oncogene 1995; 11: 2113-2120.
126. Tavner FJ, Simpson R, Tashiro S, Favier D, Jenkins NA, Gilbert DJ, Copeland NG, Macmillan EM, Lutwyche I, Keough RA, Ishii S, Gonda TJ. Molecular cloning reveals that the p160 myb-binding protein is a novel, predominantly nucleolar protein which may play a role in transactivation by myb. Mol Cell Biol 1998; 18: 989-1002.
127. Gonda TJ, Metcalf D. Expression of myb, myc, and fos proto-oncogenes during the differentiation of a murine myeloid leukemia. Nature 1984; 310: 249-251.
128. Sheiness D, Gardinier M. Expression of a proto-oncogene (proto-myb) in hemopoietic tissues of mice. Mol Cell Biol 1984; 4: 1206-1212.
129. Duprey SP, Bottinger D. Developmental regulation of c-myb in normal myeloid progenitors. Proc Natl Acad Sci USA 1985; 82: 6937-6941.
130. Ess KC, Witte DP, Bascomb CP, Aronow BJ. Diverse developing mouse lineages exhibit high-level c-myb expression in immature cells and loss of expression upon differentiation. Oncogene 1999; 18: 1103-1111.
131. Mucenski ML, McClain K, Kier AB, Swerdlow SH, Schreiner CM, Miller TA, Pietryga DW, Scott WJ, Potter SS. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell 1991; 65: 677-689.
132. Bies I, Mukhopadhyaya R, Pierce J, Wolff L. Only late, nonmitotic stages of granulocyte differentiation in 32Dcl3 cells are blocked by ectopic expression of murine c-myb and its truncated forms. Cell Growth Differ 1995; 6: 59-68.
133. Gewirtz AM, Calabretta B. A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science 1988; 242: 1303-1306.
134. Katzen AL, Jackson J, Harmon BP, Fung S-M, Ramsay G, Bishop JM. Drosophila myb is required for the G2/M transition and maintenance of diploidy. Genes Dev 1998; 12: 831-843.
135. Introna M, Golay J. How can oncogenic transcription factors cause cancer: a critical review of the myb story. Leukemia 1999; 13: 1301-1306.
136. Golay J, Erba E, Bernasconi S, Peri G, Introna M. The A-myb gene is preferentially expressed in tonsillar CD38+, CD39-, slgM-B lymphocytes and Burkitt's lymphoma cell lines. J Immunol 1994; 153: 543-553.
137. Golay J, Broccoli V, Lamorte G, Bifulco C, Parravicini C, Thomas NSB, Delia D, Ferrauti P, Vitolo D, Introna M. The A-myb transcription factor is a marker of centroblasts in vivo. J Immunol 1998; 160: 2786-2793.
138. Golay J, Capucci A, Arsura M, Castellano M, Rizzo V, Introna M. Expression of c-myb and B-myb, but not A-myb, correlates with proliferation in human hematopoietic cells. Blood 1991; 77: 149-158.
139. Reiss K, Travali S, Calabretta B, Baserga R. Growth regulated expression of B-myb in fibroblasts and hematopoietic cells. J Cell Physiol 1991; 148: 338-343.
140. McGinnis W, Garber RL, Wirz J, Kuroiwa A, Gehring WJ. A homologous protein-coding sequence in Drosophila homeotic genes and its conservation in other metazoans. Cell 1984; 37: 403-408.
141. Helgason CD, Sauvageau G, Lawrence HJ, Largman C, Humphries RK. Overexpression of HOXB4 enhances the hematopoietic potential of embryonic stem cells differentiated in vitro. Blood 1996; 87: 2740-2749.
142. Lawrence HJ, Helgason CD, Sauvageau G, Fong S, Izon D, Humphries RK, Larman C. Mice bearing targeted interruptions of the homeobox gene hoxa9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. Blood 1997; 89: 1922-1930.
143. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood 1997; 90: 489-519.
144. Fuller JF. Characterization of HOX gene expression during myelopoiesis: role of HOX A5 in lineage commitment and maturation. Blood 1999; 93: 3391-3400.
145. Allen JD, Adams JM. Enforced expression of Hlx homeobox gene promotes myeloid cell maturation and altered adherence properties of T cells. Blood 1993; 81: 3242-3251.
146. Lill MC, Fuller JF, Herzig R, Crooks GM, Gasson JC. The role of the homeobox gene, HOX B7, in human myelomonocytic differentiation. Blood 1995; 85: 692-697.
147. Reddy JC, Licht JD. The WT1 Wilms' tumor suppressor gene: how much do we really know? Biochem Biophys Acta 1996; 1287: 1-28.
148. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA 1991 ; 88: 9618-9622.
149. Sharma PM, Bowman M, Madden SL, Rauscher FJ, Sukumar SV. RNA editing in the Wilms' tumor susceptibility gene, WT1. Genes Dev 1994; 8: 720-731.
150. Rauscher FJ, Morris JF, Tournary OE, Cook DM, Curran T. Binding of the Wilms tumor locus zinc finger protein to the EGR-1 consensus sequence. Science 1990; 250: 1259-1262.
151. Wang ZY, Qiu QQ, Enger KT, Deuel TF. A second transcriptionally acitve DNA binding site for the Wilms' tumor gene product, WT1. Proc Natl Acad Sci USA 1993; 90: 8896-8900.
152. Drummond IA, Rupprecht HD, Rohwer-Nutter P, Lopez-Guisa J, Madden SL, Rauscher FJ, Sukhatme VP. DNA recognition by splicing variants of the Wilms' tumor suppressor, WT1. Mol Cell Biol 1994; 14: 3800-3809.
153. Wang, Zy, Qiu QQ, Deuel TF. The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains. J Biol Chem 1993; 268: 9172-9175.
154. Werner H, Rauscher FJ, Sukhatme VP, Drummond IA, Roberts CT, LeRoith D. Transcriptional repression of the insulin-like growth factor 1 receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J Biol Chem 1994; 269: 12577-12582.
155. Reddy JC, Hosono S, Licht JD. The transcriptional effect of WT1 is modulated by choice of expression vector. J Biol Chem 1995; 270: 29976-29982.
156. Larsson SH, Charlieu LP, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, Cuzin F, van Heyningen V, Hastie ND. Subcellular localization of WT1 in splicing or transcription factor domains is regulated by alternate splicing. Cell 1995; 81: 391-401.
157. Davies RC, Calvio C, Bratt E, Larsson SH, Lamond AI, Hastie ND. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev 1998; 12: 3217-3225.
158. Baird PN, Simmons PJ. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997; 25: 312-320.
159. Maurer U, Brieger J, Weidmann E, PS PM, Hoelzer D, Bergmann L. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 1997; 25: 945-950.
160. Sekiya M, Adachi M, Hinoda Y, Imai K, Yachi A. Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells. Blood 1994; 7: 1876-1882.
161. Phelan SA, Lindberg C, Call KM. Wilms' tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. Cell Growth Differ 1994; 5: 677-686.
162. Smith SI, Weil D, Johnson GR, Boyd AW, Li CL. Expression of the Wilms' tumor suppressor gene, WT1, is upregulated by leukemia inhibitory factor and induces monocytic differentiation in M1 leukemic cells. Blood 1998; 91: 764-773.
163. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T, Oji Y, Tsuboi A, Kim EH, Kawakami M, Akiyama T, Kishimoto T, Sugiyama H. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91: 2969-2976.
164. Englert C, Hou X, Maheswaran S, Bennett P, Ngwu C, Re GG, Garvin AJ, Rosner MR, Haber DA. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995; 14: 4662-4675.
165. Werner H, Shen-Orr Z, Rauscher FJ, Morris JF, Roberts CT, LeRoith D. Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor 1 receptor gene expression. Mol Cell Biol 1995; 15: 3516-3522.
166. Kim J, Prawitt D, Bardeesy N, Torban E, Vicaner C, Goodye PR, Zabel B, Pelletier J. The Wilms' tumor suppressor gene (wt1 ) product regulates Dax-1 gene expression during gonadal differentiation. Mol Cell Biol 1999; 19: 2289-2299.
167. Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC, Weissman BE, Baldwin AS. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 1999; 18: 3990-4003.
168. Goodyer P, Dehbi M, Torban E, Bruening W, Pelletier J. Repression of the retinoic acid receptor-α gene by the Wilms tumor suppresor gene product, wt1. Oncogene 1995; 10: 1125-1129.
169. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
170. Lee EY, Chang CY, Wang YC, Lai CC, Herrup K, Lee WH, Bradley A. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 1992; 359: 288-294.
171. Condorelli GL, Testa U, Valtieri M, Vitelli L, De Luca A, Barberi T, Montesoro E, Campisi S, Giordano A, Peschle C. Modulation of retinoblastoma gene in normal adult hematopoiesis: peak expression and functional role in advanced erythroid differentiation. Proc Natl Acad Sci USA 1995; 92: 4808-4812.
172. Bergh G, Ehinger M, Olsson I, Jacobsen SEW, Gullberg U. Involvement of the retinoblastoma protein in monocytic and neutrophilic lineage commitment of human bone marrow progenitor cells. Blood 1999; 94: 1971-1978.
173. Hagemeier C, Bannister AJ, Cook A, Kouzarides T. The activation domain of transcription factor PU.1 binds the retinoblastoma protein (RB) and the transcription factor TFIID in vitro: RB shows sequence similarity to TFIID and TFIIB. Proc Natl Acad Sci USA 1993; 90: 1580-1584.
174. Chen PL, Riley DJ, Chen-Kiang S, Lee WH. Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6. Proc Natl Acad Sci USA 1996; 93: 465-469.
175. Douer D, Koeffler HP. Retinoic acid enhaces colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro. Exp Cell Res 1982; 138: 193-198.
176. Gratas C, Menot ML, Dresch C, Chomienne C. Retinoic acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells. Leukemia 1993; 7: 1156-1162.
177. Hodges RE, Sauberlich HE, Canham JE, Wallace DL, Rucker RB, Mejia LA, Mohanram M. Hematopoietic studies in vitamin A deficiency. Am J Clin Nut 1978; 31: 876-885.
178. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line HL-60 by retinoic acid. Proc Natl Acad Sci USA 1980; 77: 2936-2940.
179. Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic leukemia cells in primary culture in response to retinoic acid. Blood 1981; 57: 1000-1004.
180. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10: 940-954.
181. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841-850.
182. de The H, Marchio A, Tiollais P, Dejean A. Differential expression and ligand regulation of the retinoic acid receptor alpha and beta genes. EMBO J 1989; 8: 429-433.
183. Umesono K, Murakami KK, Thompson CC, Evans RM. Direct repeats as selective response elements for the thyroid hormone, retinoic acid and vitamin D3 receptors. Cell 1991; 65: 1255-1266.
184. Naar AM, Boutin JM, Lipkin SM, Yu VC, Holloway JM, Glass CK, Rosenfeld MG. The orientation and spacing of core DNA-binding motifs dictate selective transcriptional responses to three nuclear receptors. Cell 1991; 65: 1267-1279.
185. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, Pelicci PG. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815-818.
186. Hong SH, David G, Wong CW, Dejean A, Privalsky ML. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor α (RARα) and PLZF-RARα oncoproteins associated with acute promyelocytic leukaemia. Proc Natl Acad Sci USA 1998; 94: 9028-9033.
187. Alland L, Muhle R, Hou H, Potes J, Chin L, Schreiber-Agus N, DePinho RA. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 1997; 387: 49-55.
188. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349-352.
189. Onate SA, Tsai SY, Tsai MJ, O'Malley B. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995; 270: 1354-1357.
190. Le Douarin B, Nielsen AL, Garnier J-M, Ichinose H, Jeanmougin F, Losson R, Chambon P. A possible involvement of TIF 1 α and TIF 1 β in the epigenetic control of transcription by nuclear receptors. EMBO J 1996; 15: 6701-6715.
191. Chen H, Lin R, Schlitz R, Chavravarti S, Nash A, Nagy L, Privalsky M, Nakatani Y, Evans R. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 1997; 90: 569-580.
192. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai M-J, O'Malley BW. Steroid receptor co-activator-1 is a histone acetyl-transferase. Nature 1997; 389: 194-198.
193. Popperl H, Featherstone MS. Identification of a retinoic acid response element upstream of the murine Hox-4.2 gene. Mol Cell Biol 1993; 13: 257-265.
194. Weihua X, Kolla V, Kalvakolanu DV. Modulation of interferon action by retinoids. Induction of murine Stat1 gene expression by retinoic acid. J Biol Chem 1997; 272: 9742-9748.
195. Chih DY, Chumakov AM, Park DJ, Silla AG, Koeffler HP. Modulation of mRNA expression of a novel human myeloid-selective CCAAT/enhancer binding protein gene (C/EBPε). Blood 1997; 90: 2987-2994.
196. Liu M, Iavarone A, Freedman LP. Transcriptional activation of the human p21(WAF/CIP1) gene by retinoic acid receptor -correlation with retinoid induction of U937 cell differentiation. J Biol Chem 1996; 271: 31723-31728.
197. Scott LM, Mueller L, Collins SJ. E3, a hematopoietic-specific transcript directly regulated by the retinoic acid receptor alpha. Blood 1996; 88: 2517-2530.
198. Tsai S, Bartelmez S, Heyman R, Damm K, Evans R, Collins SJ. A mutated retinoic acid receptor-alpha exhibiting dominant-negative activity alters the lineage development of a multipotent hematopoietic cell line. Genes Dev 1992; 6: 2558-2569.
199. Tsai S, Collins SJ. A dominant-negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage. Proc Natl Acad Sci USA 1993; 90: 7153-7157.
200. Kastner P, Mark M, Chambon P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life. Cell 1995; 83: 859-869.
201. Labrecque J, Allan D, Chambon P, Iscove NN, Lohnes D, Hoang T. Impaired granulocytic differentiation in vitro in hematopoietic cells lacking retinoic acid receptors α1 and γ. Blood 1998; 92: 607-615.
202. +) while enhancing the terminal maturation of committed granulocyte/monocyte progenitors. Blood 1999; 94: 483-495.
203. Darnell JE Jr. STATs and gene regulation. Science 1997; 277: 1630-1635.
204. Lamb P, Seidel HM, Haslam J, Milocco L, Kessler LV, Stein RB, Rosen J. STAT protein complexes activated by interferon-γ and gp130 signaling molecules differ in their sequence preferences and transcriptional induction properties. Nucleic Acids Res 1995; 23: 3283-3289.
205. Seidel HM, Milocco LH, Lamb P, Darnell JE Jr, Stein RB, Rosen J. Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc Natl Acad Sci USA 1995; 92: 3041-3045.
206. Decker T, Kovarik P, Meinke A. GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J Intefer Cytokine Res 1997; 17: 121-134.
207. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000; 95: 19-29.
208. Schaefer TS, Sanders LK, Nathans D. Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Proc Natl Acad Sci USA 1995; 92: 9097-9101.
209. Zhang JJ, Zhao Y, Chait BT, Lathem WW, Ritzi M, Knippers R, Darnell JE, Jr. Ser727-dependent recruitment of MCM5 by Stat1 α in IFN-γ-induced transcriptional activation. EMBO J 1998; 17: 6963-6971.
210. Zhu M-h, John S, Berg M, Leonard WJ. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNγ-mediated signaling. Cell 1999; 96: 121-130.
211. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995; 82: 241-250.
212. Zhang X, Blenis J, Li H-C, Schindler C, Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 1995; 267: 1990-1994.
213. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997; 278: 1803-1805.
214. Jain N, Zhang T, Fong SL, Lim CP, Cao X. Repression of Stat3 activity by activation of mitogen-activated protein kinase. Oncogene 1998; 17: 3157-3167.
215. Rajotte D, Sadowski HB, Haman A, Gopalbhai K, Meloche S, Liu L, Krystal G, Hoang T. Contribution of both STAT and SRF/TCF to c-fos promoter activation by granulocyte-macrophage colony-stimulating factor. Blood 1996; 88: 2906-2916.
216. Matsumura I, Ishikawa J, Nakajima K, Oritani K, Tomiyama Y, Miyagawa J, Kato T, Miyazaki H, Matsuzavva Y, Kanakura Y. Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21(WAF1/Cip1) by STAT5. Mol Cell Biol 1997; 17: 2933-2943.
217. Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, Miyajima A, Yoshimura A. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 1997; 89: 3148-3154.
218. Matsumura I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Alhanese C, Downward J, Pestell RG, Kanakura Y. Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J 1999; 18: 1367-1377.
219. Mui AL-F, Wakao H, O'Farrell A-M, Harada N, Miyajima A. Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J 1995; 14: 1166-1175.
220. Nicholson SE, Starr R, Novak U, Hilton DJ, Layton JE. Tyrosine residues in the granulocyte colony-stimulating receptor (G-CSF-R) mediate G-CSF-induced differentiation of murine myeloid leukemic (M1) cells. J Biol Chem 1996; 271: 26947-26953.
221. Novak U, Ward AC, Hertzog PJ, Hamilton JA, Paradiso L. Aberrant activation of JAK/STAT pathway components in response to G-CSF, interferon-alpha/beta and interferon-gamma in NFS-60 cells. Growth Factors 1996; 13: 251-260.
222. Ward AC, Hermans MHA, Smith L, van Aesch YM, Schelen AM, Antonissen C, Touw IP. Tyrosine-dependent and independent mechanisms of STAT3 activation by the human granulocyte colony-stimulating factor (G-CSF) receptor are differentially utilized depending on G-CSF concentration. Blood 1949; 93: 113-124.
223. Ward AC, van Aesch YM, Schelen AM, Touw IP. Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/acute myeloid leukemia. Blood 1999; 93: 447-458.
224. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 1997; 94: 3801-3804.
225. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998; 93: 841-850.
226. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, Kitaoka T, Fukada T, Hibi M, Hirano T. A central role for Stal3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996; 15: 3651-3658.
227. Shimozaki K, Nakajima K, Hirano T, Nagata S. Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells. J Biol Chem 1997; 272: 25184-25189.
228. Ward AC, Smith L, de Koning JP, van Aesch Y, Touw IP. Multiple signals mediate proliferation, differentiation and survival from the granulocyte colony-stimulating factor receptor in myeloid 32D cells. J Biol Chem 1999; 274: 14956-14962.
229. Dong F, Liu X, de Koning JP, Touw IP, Henninghausen L, Larner A, Grimley PM. Stimulation of Stat5 by granulocyte colony-stimulating factor (G-CSF) is modulated by two distinct cytoplasmic regions of the G-CSF receptor. J Immunol 1998; 161: 6503-6509.
230. Ward AC, van Aesch YM, Gits J, Schelen AM, de Koning JP, van Leeuwen D, Freedman MH, Touw IP. Novel point mutation in the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor in a case of severe congenital neutropenia hyporesponsive to G-CSF treatment. J Exp Med 1999; 190: 497-507.
231. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H. Sequence specific DNA binding by the c-Myc protein. Science 1990; 250: 1149-1151.
232. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991; 251: 1211-1217.
233. Watanabe S, Ishida S, Koike K, Arai K. Characterization of cis-regulatory elements of the c-myc promoter responding to human GM-CSF or mouse interleukin 3 in mouse proB cell line BA/F3 cells expressing the human GM-CSF receptor. Mol Cell Biol 1995; 6: 627-636.
234. de Koning JP, Soede-Bobok AA, Schelen AM, Smith L, van Leeuwen D, Santini V, Burgering BMT, Bos JL, Löwenberg B, Touw IP. Proliferation signaling and activation of Shc, p21Ras and Myc via tyrosine 764 of human granulocyte colony-stimulating factor receptor. Blood 1998; 91: 1924-1933.
235. Grandori C, Eisenman RN. Myc target genes. Trends in Biochem Sci 1997; 22: 177-181.
236. Cole MD. The myc oncogene: its role in transformation and differentiation. Annu Rev Genet 1986; 20: 361-384.
237. Luscher B, Christenson E, Litchfield DW, Krebs EG, Eisenman RN. Myb DNA binding inhibited by phosphorylation at a site deleted during oncogenic activation. Nature 1990; 344: 517-522.
238. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 1993; 72: 233-245.
239. kip1 is abrogated by c-Myc. EMBO J 1996; 15: 6595-6604.
240. 1 arrest through reduction of cyclin E/CDK2 kinase activity. Oncogene 1997; 15: 1347-1356.
241. Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, Kiyokawa H. Targeted disruption of CDK4 delays cell cycle entry with enhance p27Kip activity. Mol Cell Biol 1999; 19: 7011-7019.
242. Mateyak MK, Obaya AJ, Sedivy JM. C-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 1999; 19: 4672-4683.
243. Zervos AS, Gyruris J, Brent R. Mxi, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 1993; 72: 223-232.
244. Hurlin PJ, Queva C, Koskinen PJ, Steingrimsson E, Ayer DE, Copeland NG, Jenkins NA, Eisenman RN. Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J 1995; 14: 5646-5659.
245. Ayer DE, Laherty CD, Lawrence QA, Armstrong AP, Eisenman RN. Mad proteins contain a dominant transcription repressor domain. Mol Cell Biol 1996; 16: 5772-5781.
246. Cultraro CM, Bino T, Segal S. Function of the c-Myc antagonist Mad1 during a molecular switch from proliferation to differentiation. Mol Cell Biol 1997; 17: 2353-2359.
247. Schreiber-Agus N, Chin L, Chen K, Torres R, Rao G, Guida P, Skoultchi AI, DePinho RA. An amino-terminal domain of Mxi mediates anit-myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 1995; 80: 777-786.
248. Laherty CD, Yang W, Sun J, Davie JR, Seto E, Eisenman RN. Histone deacetylases associated with the mSin3 corepressor mediate Mad transcriptional repression. Cell 1997; 89: 349-356.
249. Larsson LG, Pettersson M, Oberg F, Nilsson K, Luschner B. Expression of mad, max, mxi and c-myc during induced differentiation of hematopoietic cells: opposite regulation of mad and c-myc. Oncogene 1994; 9: 1247-1252.
250. Delgado MD, Lerga A, Canelles M, Gomez-Casarez MT, Leon J. Differential regulation of Max and role of c-Myc during erythroid and myelomonocytic differentiation of K562 cells. Oncogene 1995; 10: 1659-1665.
251. Ayer DE, Kretzner L, Eisenman RN. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 1993; 72: 211-222.
252. Queva C, Hurlin PJ, Foley KP, Eisenman RN. Sequential expression of the Mad family of transcriptional repressors during differentiation and development. Oncogene 1998; 16: 967-977.
253. Foley KP, McArthur GA, Queva C, Hurlin P, Soriano P, Eisenman RN. Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation. EMBO J 1998; 17: 774-785.
254. Skalnik DG, Strauss EC, Orkin SH. CCAAT-displacement protein as a repressor of the myelomonocytic-specific gp91-phox promoter. J Biol Chem 1991; 266: 16736-16744.
255. Lou W, Skalnik DG. CCAAT displacement protein competes with multiple transcriptional activators for binding to four sites in the proximal gp91-phox promoter. J Biol Chem 1996; 271: 18203-18210.
256. Khanna-Gupta A, Zibello T, Kolla S, Neufeld EJ, Berliner N. CCAAT displacement protein (CDP/cut) recognizes a silencer element within the lactoferrin promoter. Blood 1997; 90: 2784-2795.
257. Bavisotto L, Kaushansky K, Lin N, Hromas R. Anti-sense oligonucleotides from the stage-specific myeloid zinc finger gene, MZF-1, inhibits granulopoiesis in vitro. J Exp Med 1991; 174: 1097-1101.
258. Robertson KA, Hill DP, Kelley MR, Tritt R, Crum B, Van Epps S, Srour E, Rice S, Hromas R. The myeloid zinc finger gene (MZF-1) delays retinoic acid-induced apoptosis and differentiation in myeloid leukemia cells. Leukemia 1998; 12: 690-698.
259. Ishiguro A, Spirin KS, Shiohara M, Tobler A, Gombart AF, Israel MA, Norton JD, Koeffler HP. Id2 expression increases with differentiation of human myeloid cells. Blood 1996; 87: 5225-5231.
260. Cooper CL, Brady G, Bilia F, Iscove NN, Quesenberry PJ. Expression of the Id family of helix-loop-helix regulators during growth and development in the hematopoietic system. Blood 1997; 89: 3155-3165.
261. Kreider BL, Benezra R, Rovera G, Kadesch T. Inhibition of myeloid differentiation by the helix-loop-helix protein Id. Science 1992; 255: 1700-1702.
262. Shaknovich R, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S, Zelent A, Licht JD. The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. Mol Cell Biol 1998; 18: 5533-5545.
263. Yeyati PL, Shaknovich R, Boterashvili S, Li J, Ball HJ, Waxman S, Nason-Burchenal K, Dmitrovsky E, Zelent A, Licht JD. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene 1999; 18: 925-934.
264. Lieschke GJ. CSF-deficient mice - what have they taught us? In: Bock GB, Goode JA (eds). The Molecular Basis of Cellular Defense Mechanisms. John Wiley & Sons Ltd: West Sussex, 1997, pp 60-77.
265. Liu F, Wu HY, Wesselschmidt R, Kornaga T, Link DC. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity 1996; 5: 491-501.
266. Shivdasani RA, Orkin SH. The transcriptional control of hematopoiesis. Blood 1996; 87: 4025-4039.
267. Heyworth C, Gale K, Dexter M, May G, Enver T. A GATA-2/estrogen receptor chimera functions as a ligand-dependent negative regulator of self-renewal. Genes Dev 1999; 13: 1847-1860.
268. Nuchprayoon I, Simkevich CP, Menglin L, Friedman AD, Rosmarin AD. GABP cooperates with c-myb and C/EBP to activate the neutrophil elastase promoter. Blood 1997; 89: 4546-4554.
269. Rekhtman N, Radparvar F, Evans T, Skoultchi AI. Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Genes Dev 1999; 13: 1398-1411.
270. Zhang P, Behre G, Pan J, Iwama A, Wara-Aswapati N, Radomska HS, Auron PE, Tenen DG, Sun Z. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc Natl Acad Sci USA 1999; 96: 8705-8710.
271. Sieweke MH, Tekotte H, Frampton J, Graf T. MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation. Cell 1996; 85: 49-60.
272. Hegde SP, Kumar A, Kurschner C, Shapiro LH. c-maf interacts with c-Myb to regulate transcription of an early myeloid gene during differentiation. Mol Cell Biol 1998; 18: 2729-2737.
273. Hegde SP, Zhao J, Ashmun RA, Shapiro LH. c-Maf induces monocytic differentiation and apoptosis in bipotent myeloid progenitors. Blood 1999; 94: 1578-1589.
274. Christy RJ, Kaestner KH, Geiman DE, Lane MD. CCAAT/enhancer binding protein gene promoter: binding of nuclear factors during differentiation of 3T3-L1 preadipocytes. Proc Natl Acad Sci USA 1991; 88: 2593-2597.
275. Chen H, Ray-Gallet D, Zhang P, Hetherington CJ, Gonzalez DA, Zhang D-E, Moreau-Gachelin F, Tenen DG. PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene 1995; 11: 1549-1560.
276. Kistler B, Pfisterer P, Wirth T. Lymphoid- and myeloid-specific activity of the PU.1 promoter is determined by the combinatorial action of octamer and ets transcription factors. Oncogene 1995; 11: 1095-1106.
277. Cogswell JP, Cogswell PC, Kuehl WM, Cuddihy AM, Bender TM, Engelke U, Marcu KB, Ting JPY. Mechanism of c-myc regulation by c-Myb in different cell lineages. Mol Cell Biol 1993; 13: 2858-2869.
278. Zhang X, Xing G, Fraizer GC, Saunders GF. Transactivation of an intronic hematopoietic-specific enhancer of the human Wilms' tumor 1 gene by GATA-1 and c-Myb. J Biol Chem 1997; 272: 29272-29280.
279. Fukunaga R, Ishizaka Ikeda E, Seto Y, Nagata S. Expression cloning of a receptor for murine granulocyte colony-stimulating factor. Cell 1990; 61: 341-350.
280. Avalos BR. Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 1996; 88: 761-777.
281. Okuda K, Foster R, Griffin JD. Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor. Ann NY Acad Sci 1999; 872: 305-312.
282. Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang X-Y, Algate PA, Franklin RA, Oberhaus SM, Steelman LS, McCubrey JA. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia 1999; 13: 1109-1166.
283. Dong F, van Buitenen C, Pouwels K, Hoefsloot LH, Löwenberg B, Touw IP. Distinct cytoplasmic regions of the human granulocyte colony-stimulating factor receptor involved in induction of proliferation and maturation. Mol Cell Biol 1993; 13: 7774-7781.
284. Fukunaga R, Ishizaka-Ikeda E, Nagata S. Growth and differentiation signals mediated by different regions in the cytoplasmic domain of granulocyte colony-stimulating factor receptor. Cell 1993; 74: 1079-1087.
285. Dong F, Brynes RK, Tidow N, Weite K, Löwenberg B, Touw IP. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. New Engl J Med 1995; 333: 487-493.
286. Fukunaga R, Seto Y, Mizushima S, Nagata S. Three different mRNAs encoding human granulocyte colony-stimulating factor receptor. Proc Natl Acad Sci USA 1990; 87: 8702-8706.
287. Nicholson SE, Oates AC, Harpur AG, Ziemiecki A, Wilks AF, Layton JE. Tyrosine kinase JAK1 is associated with the granulocyte-colony stimulating factor receptor and both become tyrosine phosphorylated after receptor activation. Proc Natl Acad Sci USA 1994; 91: 2985-2988.
288. Yoshikawa A, Murakami H, Nagata S. Distinct signal transduction through the tyrosine-containing domains of the granulocyte colony-stimulating factor receptor. EMBO J 1995; 14: 5288-5296.
289. de Koning JP, Dong F, Smith L, Schelen AM, Barge RM, van der Plas DC, Hoefsloot LH, Löwenberg B, Touw IP. The membrane-distal cytoplasmic region of human granulocyte colony-stimulating factor receptor is required for STAT3 but not STAT1 homodimer formation. Blood 1996; 87: 1335-1342.
290. Chakraborty A, Dyer KF, Cascio M, Mietzner TA, Tweardy DJ. Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor. Blood 1999; 93: 15-24.
291. de Koning JP, Schelen AM, Dong F, van Buitenen C, Burgering BM, Bos JL, Löwenberg B, Touw IP. Specific involvement of tyrosine 764 of human granulocyte colony-stimulating factor receptor in signal transduction mediated by p145/Shc/GRB2 or p90/GRB2 complexes. Blood 1996; 87: 132-140.
292. Barge RM, de Koning JP, Pouwels K, Dong F, Löwenberg B, Touw IP. Tryptophan 650 of human granulocyte colony-stimulating factor (G-CSF) receptor, implicated in the activation of JAK2, is also required for G-CSF-mediated activation of signaling complexes of the p21ras route. Blood 1996; 87: 2148-2153.
293. t-cel. Blood 1995; 85: 3117-3126.
294. Tian S-S, Tapley P, Sincich C, Stein RB, Rosen J, Lamb P. Multiple signaling pathways induced by granulocyte colony-stimulating factor involving activation of JAKs, STAT5, and/or STAT3 are required for regulation of three distinct classes of immediate early genes. Blood 1996; 88: 4435-4444.
295. Corey SJ, Burkhardt AL, Bolen JB, Geahlen RL, Tkatch LS, Tweardy DJ. Granulocyte colony-stimulating factor receptor signaling involves the formation of a three-component complex with Lyn and Syk protein-tyrosine kinases. Proc Natl Acad Sci USA 1994; 91: 4683-4687.
296. Corey SJ, Dombrosky-Ferlan PM, Zuo S, Krohn E, Donnenberg AD, Zurich P, Romero G, Takata M, Kurosaki T. Requirement of Src kinase Lyn for induction of DNA synthesis by granulocyte colony-stimulating factor. J Biol Chem 1998; 273: 3230-3235.
297. Ward AC, Monkhouse JL, Csar XF, Touw IP, Bello PA. The Src-like kinase Hck is activated by granulocyte colony-stimulating factor (G-CSF), and docks to the activated G-CSF receptor. Biochem Biophys Res Commun 1998; 251: 117-123.
298. Hunter MG, Avalos BR. Phosphatidylinositol 3′-kinase and SH2-containing inositol phosphatase (SHIP) are recruited by distinct positive and negative growth-regulatory domains in the granulocyte colony-stimulating factor receptor. J Immunol 1998; 160: 4979-4987.
299. Liu Q, Sasaki T, Kozieradzki I, Wakeham A, Itie A, Dumont DJ, Penninger JM. SHIP is a negative regulator of growth factor-receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev 1999; 13: 786-791.
300. Minami M, Inoue M, Wei S, Takeda K, Matsumoto M, Kishimoto T, Akira S. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci USA 1996; 93: 3963-3966.
301. de Koning JP, Smith L, Schelen AM, Lowenberg B, Touw I. STAT3 is essential for down modulation of G-CSF-induced proliferation and neutrophil differentiation. Blood 1997; 90: 597a.
302. Druker BJ, Neumann M, Okuda K, Franza BRJ, Griffin JD. rel is rapidly tyrosine phosphorylated following granulocyte-colony stimulating factor treatment of human neutrophils. J Biol Chem 1994; 269: 5387-5390.
303. Betsuyaku T, Liu F, Senior RM, Haug JS, Brown EJ, Jones SL, Matsushima K, Link DC. A functional granulocyte colony-stimulating factor receptor is required for normal chemotractant-induced neutrophil activation. J Clin Invest 1999; 103: 825-832.
304. Dong F, Dale DC, Bonilla MA, Freedman M, Fasth A, Neijens HJ, Palmblad J, Briars GL, Carlsson G, Veerman AJ, Weite K, Löwenberg B, Touw IP. Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Leukemia 1997; 11: 120-125.
305. Hermans MHA, Ward AC, Antonissen C, Karis A, Lowenberg B, Touw IP. Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia. Blood 1998; 92: 32-39.
306. Lagasse E, Weissman IL. Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reversesosteopetrosis in op/op mice. Cell 1997; 89: 1021-1031.
307. Akashi K, Kondo M, von Freeden-Jeffry U, Murray R, Weissman IL. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell 1997; 89: 1033-1041.
308. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278: 1309-1312.
309. Rodel JE, Link DC. Suppression of apoptosis during cytokine deprivation of 32D cells is not sufficient to induce complete granulocytic differentiation. Blood 1996; 87: 858-864.
310. Rausch O, Marshall CJ. Tyrosine 763 of the murine granulocyte colony-stimulating factor receptor mediates Ras-dependent activation of the JNK/SAPK mitogen-activated protein kinase pathway. Mol Cell Biol 1997; 17: 1170-1179.
311. Bassuk AG, Leiden JM. A direct physical association between ETS and AP-1 transcription factors in normal human T cells. Immunity 1995; 3: 223-237.
312. Behre G, Whitmarsh AJ, Coghlan MP, Hoang T, Carpenter CL, Zhang D-E, Davis RJ, Tenen DG. c-Jun is a JNK-independent coactivator of the PU.1 transcription factor. J Biol Chem 1999; 274: 4939-4946.
313. Li AC, Guidez FRB, Collier G, Glass CK. The macrosialin promoter directs high levels of transcriptional activity in macrophages dependent on combinatorial interactions between PU.1 and c-Jun. J Biol Chem 1998; 273: 5389-5399.
314. Nakajima T, Kinoshita S, Sasagawa T, Sasaki K, Naruto M, Kishimoto T, Akira S. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci USA 1993; 90: 2207-2211.
315. Behre G, Smith LT, Carpenter CL, Hiddemann W, Friedman AD, Tenen DG. Ras enhances the ability of C/EBPα to transactivate the G-CSF receptor promoter by phosphorylation of serine 248 of the C/EBPα transactivation domain. Blood 1998; 94: 68a.
316. Kowenz-Leutz E, Herr P, Niss K, Leutz A. The homeobox gene GBX2, a target of the myb oncogene, mediates autocrine growth and monocyte differentiation. Cell 1997; 91: 185-195.
317. Leverson JD, Koskienen PJ, Orrico FC, Rainio EM, Jalkanen KJ, Dash EB, Eisenman RN, Ness SA. Pim-1 kinase and p100 cooperate to enhance c-Myb activity. Mol Cell 1998; 2: 417-425.
318. Kip1 in
319. Umek RM, Friedman AD, McKnight SL. CCAAT-enhancer binding protein: a component of a differentiation switch. Science 1991; 251: 288-292.
320. Ramos RA, Nishio Y, Maiyar AC, Simon KE, Ridder CC, Ge Y, Firestone GL. Glucocorticoid-stimulated CCAAT/enhancer-binding protein alpha expression is required for steroid-induced cell cycle arrest of minimal-deviation rat hepatoma cells. Mol Cell Biol 1996; 16: 5288-5301.
321. Timchenko NA, Wilde M, Darlington GJ. C/EBPa regulates formation of S-phase-specific E2F-p107 complexes in livers of newborn mice. Mol Cell Biol 1999; 19: 2936-2945.
322. Johansen LM, Iwama A, Golub TR, Tenen DG. c-myc is a critical target for C/EBPα in granulopoiesis. Blood 1999; 94: 59a.
323. Wang W, Wang X, Ward A, Touw I, Friedman AD. C/EBPa and G-CSF receptor signals cooperate to induce the myeloperoxidase and neutrophil elastase genes. Blood 1999; 94: 684a.
324. Orita T, Shimozaki K, Murakami H, Nagata S. Binding of NF-Y transcription factor to one of the cis-elements in the myeloperoxidase gene promoter that responds to granulocyte colony-stimulating factor. J Biol Chem 1997; 272: 23216-23223.
325. Zhang P, Iwama A, Datta MW, Darlington GJ, Link DC, Tenen DG. Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein a (C/EBPα) is critical for granulopoiesis. J Exp Med 1998; 188: 1173-1184.
326. Yang F-C, Tsuji K, Oda A, Ebihara Y, Xu M, Kaneko A, Hanada S, Mitsui T, Kikuchi A, Manabe A, Watanabe S, Ikeda Y, Nakahata T. Differential effects of human granulocyte colony-stimulating factor (hG-CSF) and thrombopoietin on megakaryopoiesis and platelet function in hG-CSF receptor-transgenic mice. Blood 1999; 94: 950-958.
327. Dorsch M, Danial NN, Rothman PB, Goff SP. A thrombopoietin receptor mutant deficient in Jak-STAT activation mediates proliferation but not differentiation in UT-7 cells. Blood 1999; 94: 2676-2685.